Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Oct 6;82(19):3580-3597.e9.
doi: 10.1016/j.molcel.2022.09.005.

p300/CBP sustains Polycomb silencing by non-enzymatic functions

Affiliations

p300/CBP sustains Polycomb silencing by non-enzymatic functions

George Hunt et al. Mol Cell. .

Abstract

Maintenance of appropriate cell states involves epigenetic mechanisms, including Polycomb-group (PcG)-mediated transcriptional repression. While PcG proteins are known to induce chromatin compaction, how PcG proteins gain access to DNA in compact chromatin to achieve long-term silencing is poorly understood. Here, we show that the p300/CREB-binding protein (CBP) co-activator is associated with two-thirds of PcG regions and required for PcG occupancy at many of these in Drosophila and mouse cells. CBP stabilizes RNA polymerase II (Pol II) at PcG-bound repressive sites and promotes Pol II pausing independently of its histone acetyltransferase activity. CBP and Pol II pausing are necessary for RNA-DNA hybrid (R-loop) formation and nucleosome depletion at Polycomb Response Elements (PREs), whereas transcription beyond the pause region is not. These results suggest that non-enzymatic activities of the CBP co-activator have been repurposed to support PcG-mediated silencing, revealing how chromatin regulator interplay maintains transcriptional states.

Keywords: CBP; Pol II pausing; Polycomb; R-loop; epigenetics; gene silencing; nucleosome depletion; p300; transcription.

PubMed Disclaimer

Conflict of interest statement

Declaration of interests A.B. is an employee and shareholder of Dewpoint Therapeutics and a former advisor to Syros Pharmaceuticals.

Publication types

MeSH terms